GKOS Nov 2024 125.000 call

OPR - OPR Delayed Price. Currency in USD

11.60

0.00

(0.00%)

At close: 03:04PM EDT

Zacks
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
Pharmaceutical Technology
Glaukos eyes FDA approval for ocular therapy after Phase III win
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).